Why a Compounded GLP-1 Won't Ship to Your State: Licenses and the MOU
When a compounded GLP-1 service says "we don't serve your state," it usually means one of two licensing gates is closed: no prescriber on its roster is licensed where you are, or its dispensing pharmacy doesn't hold a license to ship into your state. A third gate, the federal interstate compounding limit in section 503A, exists on paper but FDA has said it will not enforce it until a final rule takes effect.
Key takeaways
- A telehealth prescriber generally must be licensed in the state where you are physically located during the visit, not where the clinician lives.
- A pharmacy that mails medication into your state typically needs a separate "nonresident" license from your state's board of pharmacy.
- Federal law caps out-of-state distribution at 5% of a 503A pharmacy's prescriptions in states without an FDA agreement, but FDA has paused enforcement of that cap pending rulemaking.
- A license lets a pharmacy operate. It is not FDA approval of the drug: compounded semaglutide and tirzepatide are not FDA-approved.
- You can check the first two gates yourself in about 15 minutes using public license lookups.
Gate 1: The prescriber must be licensed where you are
State medical boards regulate the practice of medicine based on where the patient is located. The Medical Board of California puts it plainly: "Physicians using telehealth technologies to provide care to patients located in California must be licensed in California" (Medical Board of California). The physician does not have to live in California, but they need an active California license.
Federal telehealth guidance points in the same direction. HHS advises clinicians to "verify patient location" before a telehealth appointment, and notes that a full license lets a provider practice in the state that issued it (HHS Telehealth). Interstate licensure compacts can speed up the process of getting licensed in more states, but they work by streamlining licensing while "preserving state oversight," not by removing the need for authorization in your state.
For a telehealth company, this is a staffing problem. If none of its physicians, nurse practitioners, or physician assistants holds a license in your state, it cannot legally write your prescription, no matter where its pharmacy is.
Gate 2: The pharmacy needs a license to ship into your state
Many states require an out-of-state pharmacy that mails prescriptions to their residents to hold a nonresident pharmacy license (some states call it a registration or permit). California's Board of Pharmacy application tells applicants they "shall not conduct business with California unless and until a license is issued" (California Board of Pharmacy nonresident application).
Nonresident licensing is not a rubber stamp. California's application requires a verification of the home-state license and the most recent home-state inspection report, ownership disclosures, fingerprinting, and a nonrefundable base application fee of $2,427. Starting July 1, 2026, a nonresident pharmacy must also name a pharmacist-in-charge who holds a California pharmacist license and works at that pharmacy (California Board of Pharmacy). The same application asks whether the pharmacy holds sterile compounding licenses, which California handles as a separate nonresident application.
Each state sets its own requirements, so it is unsurprising that a pharmacy may be licensed to ship into some states and not others. When a pharmacy's license in your state lapses, is pending, or was never obtained, the telehealth company that routes prescriptions to it will usually exclude your state.
Compare current GLP-1 options
Review which care options list your state, then verify each prescriber and pharmacy license yourself.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Gate 3: The federal 5% limit and FDA's interstate MOU
Section 503A of the Federal Food, Drug, and Cosmetic Act is the federal law that lets state-licensed pharmacies compound for individual patients without FDA approval. One of its conditions concerns interstate distribution. In a state that has not signed a memorandum of understanding (MOU) with FDA, a pharmacy may distribute compounded drugs out of state only "in quantities that do not exceed 5 percent of the total prescription orders" it dispenses or distributes (21 U.S.C. 353a(b)(3)(B)).
FDA finalized a standard MOU in October 2020 and gave states 365 days to sign before it would enforce the 5% limit in non-signing states (FDA Brief, Oct. 26, 2020). The deadline was later moved. In an October 2022 Federal Register notice, FDA said it was extending the period, "which was scheduled to end on October 27, 2022, until the effective date of a final rule," along with publication of an updated standard MOU. The same notice says FDA "considers the standard MOU published in October 2020 to be suspended" and "will not enter into new agreements with States based on the October 2020 standard MOU" (Federal Register, Oct. 21, 2022). FDA's MOU page is where any update would be posted.
What that means in practice: until a final rule takes effect, FDA has said it will not begin enforcing the 5% cap, so it is not the usual reason a service turns you away. Check FDA's MOU page for any change. It could matter in the future if FDA completes rulemaking. Until then, Gates 1 and 2 are the ones that decide whether a service can serve you.
Decision table: which gate is probably closed?
| What the service tells you | Most likely gate | What you can check |
|---|---|---|
| "We don't have providers in your state" | Gate 1 (prescriber license) | State medical or nursing board lookup for any clinician they name |
| "Our pharmacy can't ship to your state" | Gate 2 (nonresident pharmacy license) | Your state pharmacy board's nonresident license lookup |
| "Your state isn't supported for this medication" | Either gate, or a state rule specific to compounding | Ask which gate; then check both boards |
| "We'll ship, but from a different pharmacy than usual" | Gate 2 for their primary pharmacy | Verify the new pharmacy's license in your state |
| "Federal law limits how much we can ship out of state" | Gate 3 (503A 5% limit) | FDA's MOU page; enforcement paused until a final rule takes effect |
Source: 21 U.S.C. 353a; FDA MOU page; California Board of Pharmacy; Medical Board of California. Verified October 19, 2026.
How to check each gate yourself
- Get names, not brands. Ask the service for the full name of the prescriber who would sign your prescription and the legal name and address of the dispensing pharmacy. A telehealth brand name is not a license holder.
- Check the prescriber. Search your state medical board's license lookup (or the nursing board, for a nurse practitioner). Confirm the license is active and note any public discipline.
- Find your pharmacy board. NABP keeps a directory of every state board of pharmacy, with phone numbers and website links (NABP directory).
- Check the pharmacy's license in your state. In your board's lookup, search for the pharmacy as a nonresident (or out-of-state) pharmacy. A home-state license alone is not enough.
- Check its home-state license too. Look the pharmacy up in the state where it is located. Active, unrestricted, no current discipline is what you want to see.
- Confirm the label matches. When the package arrives, the pharmacy named on the label should be the one you verified. FDA recommends buying only from state-licensed pharmacies (FDA).
Worked example
Suppose a reader in California is told a service "can't currently serve California." She asks support two questions: which clinician would prescribe, and which pharmacy would fill. Support names a physician licensed in Texas and Arizona, and a pharmacy in Florida.
She searches the Medical Board of California lookup and finds no California license for the physician. That alone explains the refusal under Gate 1. She also searches the California Board of Pharmacy for the Florida pharmacy as a nonresident pharmacy and finds no listing, so Gate 2 would block the order too. Her takeaway is that the service is following the rules, not dodging her. Any service that would ship anyway, with the same prescriber and pharmacy, would be the bigger concern.
This example is illustrative. It does not describe any real company or person.
Scenario guidance
You moved, or you're spending months in another state
Your existing prescriber may not be licensed where you now are. Tell the service your current location before your next visit. Continuing care across state lines without the right license can expose the prescriber, and it can leave you without a valid prescription for refills.
A service offers to "work around" your state
Be cautious with any offer to ship to a friend's address in another state or to list a different location. It undermines the licensing checks that exist to protect you, and it may mean the prescription was issued under false facts.
A site ships everywhere with no questions
Universal shipping is possible for a large, fully licensed operation, but it is also a pattern seen with unlicensed sellers. Run the six checks above. If the seller won't name a pharmacy, treat that as an answer.
Questions to ask the service, prescriber, or pharmacy
- Which clinician will prescribe, and in which states is that person licensed?
- What is the legal name and address of the dispensing pharmacy?
- Does that pharmacy hold a nonresident license in my state? What is the license number?
- Is it a 503A pharmacy or a 503B outsourcing facility?
- If the pharmacy changes, will you tell me before shipping?
- What happens to my prescription if I travel or move?
Where this guide stops
This guide explains general licensing structure. It does not cover every state's nonresident rules, nurse practitioner and physician assistant practice rules, or state laws aimed specifically at compounded GLP-1s, all of which vary. It is not legal advice and not medical advice. For your situation, contact your state's medical and pharmacy boards, and talk with your prescriber about whether a compounded product is appropriate for you at all.
Compare available care options
If you're weighing services that do list your state, verify the prescriber's and the pharmacy's credentials and read the terms yourself. A listing is not a recommendation or a prescription.
Compare participating providers
See which care options serve your state, then run the license checks above before you order.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Disclosure: we may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legitimacy, or value.
Frequently asked questions
Why won't a compounded semaglutide service ship to my state?
Usually because no prescriber on its roster is licensed in your state, or because its dispensing pharmacy lacks a nonresident license to ship there. Both are state licensing requirements.
Does a telehealth doctor need a license in my state?
Generally yes. State medical boards regulate care based on where the patient is located; the Medical Board of California, for example, says physicians treating patients located in California by telehealth must hold a California license.
Is the federal 5% interstate compounding limit being enforced?
No. In an October 2022 Federal Register notice, FDA extended the period before it will enforce the 5% limit in states without an MOU until the effective date of a final rule, and said it considers the 2020 standard MOU suspended. Check FDA's MOU page for any change.
Does a pharmacy license mean compounded semaglutide is FDA-approved?
No. A license lets a pharmacy operate in a state. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they reach patients.
How can I check whether a pharmacy can legally ship to me?
Get the pharmacy's legal name and address, find your state board of pharmacy through NABP's directory, and search for the pharmacy as a nonresident pharmacy. Also confirm its home-state license is active.
Sources
- Medical Board of California: Telehealth
- HHS Telehealth: Licensing across state lines
- California State Board of Pharmacy: Nonresident pharmacy application packet
- 21 U.S.C. 353a (FD&C Act section 503A), Cornell LII
- FDA Brief: Final standard MOU on compounded drug distribution (Oct. 26, 2020)
- Federal Register: Extension of the Period Before FDA Intends To Begin Enforcing the Statutory 5 Percent Limit on Out-of-State Distribution of Compounded Human Drug Products (Oct. 21, 2022)
- FDA: Memorandum of understanding addressing certain distributions of compounded drugs
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026)
- NABP: Boards of pharmacy directory
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss
- FDA: Compounding laws and policies
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.